Eli Lilly's Pricing Strategy and Industry Impacts

This chapter discusses Eli Lilly's new pricing strategy for its weight loss drug, ZEPBOUND, aimed at improving accessibility. The implications of this move on the pharmaceutical market, particularly against competitors and in terms of drug administration methods, are explored. Additionally, the chapter touches on the role of compounders in addressing drug shortages and the broader context of drug pricing scrutiny in the industry.